172 related articles for article (PubMed ID: 38175687)
41. Modulating the tumor immune microenvironment with nanoparticles: A sword for improving the efficiency of ovarian cancer immunotherapy.
Xu T; Liu Z; Huang L; Jing J; Liu X
Front Immunol; 2022; 13():1057850. PubMed ID: 36532066
[TBL] [Abstract][Full Text] [Related]
42. The role of tumor-associated macrophage in breast cancer biology.
Choi J; Gyamfi J; Jang H; Koo JS
Histol Histopathol; 2018 Feb; 33(2):133-145. PubMed ID: 28681373
[TBL] [Abstract][Full Text] [Related]
43. Tumor-associated macrophages of the M1/M2 phenotype are involved in the regulation of malignant biological behavior of breast cancer cells through the EMT pathway.
Chen Z; Wu J; Wang L; Zhao H; He J
Med Oncol; 2022 May; 39(5):83. PubMed ID: 35570226
[TBL] [Abstract][Full Text] [Related]
44. Single-cell and transcriptomic analyses reveal the influence of diabetes on ovarian cancer.
Zhao Z; Wang Q; Zhao F; Ma J; Sui X; Choe HC; Chen P; Gao X; Zhang L
BMC Genomics; 2024 Jan; 25(1):1. PubMed ID: 38166541
[TBL] [Abstract][Full Text] [Related]
45. CD4+ conventional T cells-related genes signature is a prognostic indicator for ovarian cancer.
Hua T; Liu DX; Zhang XC; Li ST; Yan P; Zhao Q; Chen SB
Front Immunol; 2023; 14():1151109. PubMed ID: 37063862
[TBL] [Abstract][Full Text] [Related]
46. Targeting tumor-associated macrophages as an antitumor strategy.
Cheng N; Bai X; Shu Y; Ahmad O; Shen P
Biochem Pharmacol; 2021 Jan; 183():114354. PubMed ID: 33279498
[TBL] [Abstract][Full Text] [Related]
47. Tumor-associated macrophages mediate gastrointestinal stromal tumor cell metastasis through CXCL2/CXCR2.
Cai H; Chen Y; Chen X; Sun W; Li Y
Cell Immunol; 2023 Feb; 384():104642. PubMed ID: 36577281
[TBL] [Abstract][Full Text] [Related]
48. Tumor stemness score to estimate epithelial-to-mesenchymal transition (EMT) and cancer stem cells (CSCs) characterization and to predict the prognosis and immunotherapy response in bladder urothelial carcinoma.
Zhang Y; Zhang X; Huang X; Tang X; Zhang M; Li Z; Hu X; Zhang M; Wang X; Yan Y
Stem Cell Res Ther; 2023 Feb; 14(1):15. PubMed ID: 36721217
[TBL] [Abstract][Full Text] [Related]
49. BRD4 Inhibition by AZD5153 Promotes Antitumor Immunity via Depolarizing M2 Macrophages.
Li X; Fu Y; Yang B; Guo E; Wu Y; Huang J; Zhang X; Xiao R; Li K; Wang B; Hu J; Sun C; Chen G
Front Immunol; 2020; 11():89. PubMed ID: 32184777
[TBL] [Abstract][Full Text] [Related]
50. Identification of peripheral blood immune infiltration signatures and construction of monocyte-associated signatures in ovarian cancer and Alzheimer's disease using single-cell sequencing.
Zhao S; Ye B; Chi H; Cheng C; Liu J
Heliyon; 2023 Jul; 9(7):e17454. PubMed ID: 37449151
[TBL] [Abstract][Full Text] [Related]
51. Single-cell transcriptomics identify TNFRSF1B as a novel T-cell exhaustion marker for ovarian cancer.
Gao Y; Shi H; Zhao H; Yao M; He Y; Jiang M; Li J; Li Z; Su S; Liu T; Yin C; Liao X; Yue W
Clin Transl Med; 2023 Sep; 13(9):e1416. PubMed ID: 37712139
[TBL] [Abstract][Full Text] [Related]
52. Methionine enkephalin suppresses lung cancer metastasis by regulating the polarization of tumor-associated macrophages and the distribution of myeloid-derived suppressor cells in the tumor microenvironment and inhibiting epithelial-mesenchymal transition.
Zhang S; Geng J; Shan F; Shan Y; Griffin N; Wu B; Wang X
Int Immunopharmacol; 2023 May; 118():110064. PubMed ID: 36989897
[TBL] [Abstract][Full Text] [Related]
53. The enhancer RNA ADCY10P1 is associated with the progression of ovarian cancer.
Mo J; Zhang L; Li H; Duan H; Wang D; Zhao X; Xie Y
J Ovarian Res; 2022 May; 15(1):61. PubMed ID: 35568893
[TBL] [Abstract][Full Text] [Related]
54. Upregulation of IGF1 by tumor-associated macrophages promotes the proliferation and migration of epithelial ovarian cancer cells.
Liu L; Wang X; Li X; Wu X; Tang M; Wang X
Oncol Rep; 2018 Feb; 39(2):818-826. PubMed ID: 29251331
[TBL] [Abstract][Full Text] [Related]
55. Effects of miR-492 on migration, invasion, EMT and prognosis in ovarian cancer by targeting SOX7.
Wang Z; Liu Y; Wang M; Zhao J
J BUON; 2020; 25(2):797-804. PubMed ID: 32521870
[TBL] [Abstract][Full Text] [Related]
56. Multi-Omics Analysis Showed the Clinical Value of Gene Signatures of C1QC
Li X; Zhang Q; Chen G; Luo D
Front Immunol; 2021; 12():694801. PubMed ID: 34295336
[TBL] [Abstract][Full Text] [Related]
57. Siglec-9
Wang Y; He M; Zhang C; Cao K; Zhang G; Yang M; Huang Y; Jiang W; Liu H
J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37709296
[TBL] [Abstract][Full Text] [Related]
58. Targeting tumor-associated macrophages for successful immunotherapy of ovarian carcinoma.
Truxova I; Cibula D; Spisek R; Fucikova J
J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36822672
[TBL] [Abstract][Full Text] [Related]
59. CircRNA FGFR3 induces epithelial-mesenchymal transition of ovarian cancer by regulating miR-29a-3p/E2F1 axis.
Zhou J; Dong ZN; Qiu BQ; Hu M; Liang XQ; Dai X; Hong D; Sun YF
Aging (Albany NY); 2020 Jul; 12(14):14080-14091. PubMed ID: 32668414
[TBL] [Abstract][Full Text] [Related]
60. Identification of the immune subtype of ovarian cancer patients by integrated analyses of transcriptome and single-cell sequencing data.
Wang S; Wang X; Xia X; Zhang T; Yi M; Li Z; Jiang L; Yang Y; Fu J; Fang X
Sci Rep; 2022 Aug; 12(1):13296. PubMed ID: 35918500
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
